Actavis plc - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Actavis plc - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Actavis plc - Product Pipeline Review - 2015', provides an overview of the Actavis plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Actavis plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Actavis plc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Actavis plc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Actavis plc's pipeline products

Reason to Buy

- Evaluate Actavis plc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Actavis plc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Actavis plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Actavis plc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actavis plc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Actavis plc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
Actavis plc Snapshot 7
Actavis plc Overview 7
Key Information 7
Key Facts 7
Actavis plc - Research and Development Overview 8
Key Therapeutic Areas 8
Actavis plc - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Actavis plc - Pipeline Products Glance 17
Actavis plc - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Filing rejected/Withdrawn Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Actavis plc - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Actavis plc - Early Stage Pipeline Products 22
IND/CTA Filed Products/Combination Treatment Modalities 22
Discovery Products/Combination Treatment Modalities 23
Actavis plc - Drug Profiles 24
APT-1026 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
cariprazine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
norethindrone 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
(aclidinium bromide + formoterol fumarate) 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
(ceftazidime + avibactam sodium) 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
bimatoprost 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
cyclosporine 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
dalbavancin 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
follitropin alfa (recombinant) 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
onabotulinumtoxin A 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pancrelipase DR 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
sarecycline hydrochloride 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
udenafil 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ulipristal acetate 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
WC-3011 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(ceftaroline fosamil + avibactam sodium) 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
memantine hydrochloride 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
oxybutynin chloride 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
EUR-1100 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AGN-232411 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Progesterone Second Generation 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
bezafibrate ER 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Actavis plc - Pipeline Analysis 57
Actavis plc - Pipeline Products by Target 57
Actavis plc - Pipeline Products by Route of Administration 59
Actavis plc - Pipeline Products by Molecule Type 60
Actavis plc - Pipeline Products by Mechanism of Action 61
Actavis plc - Recent Pipeline Updates 63
Actavis plc - Dormant Projects 83
Actavis plc - Discontinued Pipeline Products 85
Discontinued Pipeline Product Profiles 85
alvameline maleate 85
dexamethasone 85
dexloxiglumide 85
ME-1036 85
neramexane mesylate 86
oglemilast 86
onabotulinumtoxin A 86
radiprodil 86
Actavis plc - Company Statement 87
Actavis plc - Locations And Subsidiaries 92
Head Office 92
Other Locations & Subsidiaries 92
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables

Actavis plc, Key Information 7
Actavis plc, Key Facts 7
Actavis plc - Pipeline by Indication, 2015 10
Actavis plc - Pipeline by Stage of Development, 2015 12
Actavis plc - Monotherapy Products in Pipeline, 2015 13
Actavis plc - Combination Treatment Modalities in Pipeline, 2015 14
Actavis plc - Partnered Products in Pipeline, 2015 15
Actavis plc - Partnered Products/ Combination Treatment Modalities, 2015 16
Actavis plc - Pre-Registration, 2015 17
Actavis plc - Filing rejected/Withdrawn, 2015 18
Actavis plc - Phase III, 2015 19
Actavis plc - Phase II, 2015 20
Actavis plc - Phase I, 2015 21
Actavis plc - IND/CTA Filed, 2015 22
Actavis plc - Discovery, 2015 23
Actavis plc - Pipeline by Target, 2015 57
Actavis plc - Pipeline by Route of Administration, 2015 59
Actavis plc - Pipeline by Molecule Type, 2015 60
Actavis plc - Pipeline Products by Mechanism of Action, 2015 61
Actavis plc - Recent Pipeline Updates, 2015 63
Actavis plc - Dormant Developmental Projects,2015 83
Actavis plc - Discontinued Pipeline Products, 2015 85
Actavis plc, Subsidiaries 92